AURANSA ​

Founded in 2012 by Pek Lum, Auransa is a biotechnology firm that leverages artificial intelligence to develop precision medicines for a wide range of diseases, with an initial focus on oncology. The company's core is its proprietary SMarTR™ AI platform, which analyzes molecular data to uncover novel disease biology and predict which patient groups will respond to specific treatments. This data-driven approach aims to de-risk the drug development process and increase the probability of clinical success.

Auransa's business model revolves around developing its own pipeline of drug candidates while also establishing strategic partnerships with pharmaceutical companies. Revenue is generated through milestone payments and future royalties from these collaborations, in addition to the value created by its internal drug pipeline. The company targets complex diseases that have been challenging to treat, using its computational platform to identify new drug targets and biomarkers.

The SMarTR™ platform integrates vast amounts of genomic and molecular data from both public and private sources. It then applies sophisticated algorithms to build predictive models of disease, moving beyond single-target approaches to understand the complex interactions within biological systems. This enables the identification of patient subgroups most likely to benefit from a particular therapy, a key component of precision medicine. The ultimate goal is to create more effective and safer medicines by matching the right drug to the right patient.

Keywords: precision medicine, biotechnology, artificial intelligence, drug discovery, oncology, computational biology, genomic data, drug development, therapeutic pipeline, precision oncology